1. Home
  2. NNNN vs ECC Comparison

NNNN vs ECC Comparison

Compare NNNN & ECC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NNNN
  • ECC
  • Stock Information
  • Founded
  • NNNN 2021
  • ECC 2014
  • Country
  • NNNN Germany
  • ECC United States
  • Employees
  • NNNN N/A
  • ECC N/A
  • Industry
  • NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ECC
  • Sector
  • NNNN Health Care
  • ECC
  • Exchange
  • NNNN Nasdaq
  • ECC NYSE
  • Market Cap
  • NNNN 369.6M
  • ECC N/A
  • IPO Year
  • NNNN 2025
  • ECC N/A
  • Fundamental
  • Price
  • NNNN $49.26
  • ECC $7.55
  • Analyst Decision
  • NNNN
  • ECC Buy
  • Analyst Count
  • NNNN 0
  • ECC 2
  • Target Price
  • NNNN N/A
  • ECC $9.25
  • AVG Volume (30 Days)
  • NNNN 220.1K
  • ECC 1.2M
  • Earning Date
  • NNNN 01-01-0001
  • ECC 08-05-2025
  • Dividend Yield
  • NNNN N/A
  • ECC 24.62%
  • EPS Growth
  • NNNN N/A
  • ECC N/A
  • EPS
  • NNNN 0.06
  • ECC N/A
  • Revenue
  • NNNN $8,185,146.00
  • ECC $191,298,536.00
  • Revenue This Year
  • NNNN N/A
  • ECC $26.00
  • Revenue Next Year
  • NNNN N/A
  • ECC $9.62
  • P/E Ratio
  • NNNN $911.18
  • ECC N/A
  • Revenue Growth
  • NNNN 21.95
  • ECC 29.29
  • 52 Week Low
  • NNNN $5.18
  • ECC $6.54
  • 52 Week High
  • NNNN $53.61
  • ECC $10.11
  • Technical
  • Relative Strength Index (RSI)
  • NNNN N/A
  • ECC 40.88
  • Support Level
  • NNNN N/A
  • ECC $7.74
  • Resistance Level
  • NNNN N/A
  • ECC $7.83
  • Average True Range (ATR)
  • NNNN 0.00
  • ECC 0.08
  • MACD
  • NNNN 0.00
  • ECC 0.01
  • Stochastic Oscillator
  • NNNN 0.00
  • ECC 17.50

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.

Share on Social Networks: